Latest Biotech News

Apogee Therapeutics secured a promise of up to $1.3 billion in nondilutive financing from Blackstone Life Sciences to advance zumilokibart into Phase 3. The move follows positive Phase 2 data...

Parse Biosciences, a Qiagen unit, partnered with bit.bio to build a transcription factor-driven cell identity map intended to support AI-driven therapy design and human cell manufacturing. The...

Verici Dx validated a 29-gene RNA expression immune signature that can predict early acute kidney rejection risk before transplantation. The company said its Pre-Transplant Risk Assessment (PTRA)...

A genetics study reported in the latest work on human immune evolution found that archaic Neandertal DNA segments can alter modern human immunity to common DNA viruses. The research reframes...

The American Cancer Society updated colorectal cancer screening guidelines to incorporate additional noninvasive tests, including new blood-based and at-home stool options. The guidance, published...

Olympus agreed to acquire BioProtect for $270 million, aiming to broaden its urology and oncology offerings with an implant-based prostate cancer spacing technology. BioProtect’s Balloon Spacer is...

Verge Genomics rebranded as Verge Labs after reporting an early-stage clinical trial failure for its AI-designed ALS candidate VRG50635. The company said it laid off about 90% of its workforce as...

Waypoint Bio raised $20 million in Series A funding to test multiple CAR-T programs in China, according to company-reported plans. The New York City startup said the financing is intended to...

Kailera Therapeutics’ triple-acting obesity drug generated double-digit weight loss in a China-based Phase 1 dosing study with partner Hengrui Pharmaceuticals. In the 12-week data set,...

The FDA has delayed its decision on AstraZeneca’s oral SERD camizestrant after an advisory committee voted against approval for a first-line breast cancer indication. AstraZeneca said the extra...

Kardigan filed for a U.S. IPO while positioning a late-stage cardiovascular precision medicine pipeline with no approved options in several targeted niches. The company plans to use proceeds to...

Apogee Therapeutics secured up to $1.3 billion in financing from Blackstone Life Sciences to fund Phase 3 development and potential commercialization of its long-acting atopic dermatitis therapy...

Parse Biosciences, a Qiagen unit, and bit.bio agreed to build a transcription factor-driven cell identity map by combining bit.bio’s cell programming and discovery platform with Parse’s Evercode...

Eli Lilly offered to acquire three vaccine companies for up to $3.8 billion, expanding its infectious disease prevention portfolio beyond its established cardiometabolic franchise. The deals...

WuXi Biologics signed manufacturing deals to support Viridian’s thyroid eye disease program, reflecting continued demand for CDMO capacity even as providers navigate policy and regulatory...

The American Cancer Society updated colorectal cancer screening guidelines to include additional blood- and stool-based options, while refining how clinicians should choose among tests. The new...

NICE approved payer reimbursement for Genmab’s tisotumab vedotin (Tivdak) for advanced recurrent or metastatic cervical cancer in updated draft-to-final guidance. NICE had previously rejected the...

ClearNote Health raised $52 million in Series D financing, bringing total funding to more than $185 million. The round was led by founding investor Mattias Westman and included participation from...

AstraZeneca said the FDA pushed back its decision on camizestrant, its oral selective estrogen receptor degrader (SERD), after an FDA advisory committee voted against approval for a first-line use...

Eli Lilly agreed to buy three vaccine developers in separate deals totaling up to $3.8 billion, expanding its infectious-disease portfolio beyond its established cardiometabolic franchises. The...